je.st
news
Home
› Gilead Initiates Phase 3 Clinical Program For Tenofovir Alafenamide, A Novel Low-Dose Prodrug For The Treatment Of HIV
Gilead Initiates Phase 3 Clinical Program For Tenofovir Alafenamide, A Novel Low-Dose Prodrug For The Treatment Of HIV
2013-01-24 09:30:00| drugdiscoveryonline News Articles
Gilead Sciences, Inc. recently announced the initiation of the first of two Phase 3 clinical trials (Study 104) evaluating a single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults
Tags: the
of
program
treatment
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||